SEC

The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order. 

The company, which also said it is short on funds, may have to pay $18.3 million to Hudson Bay Master Fund if forebearance is not granted for the default.

Insider Info

A clinical trial PI faces insider-trading charges, according to Pharmalot's Ed Silverman.

The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.

The company previously said in an SEC document that it raised $16.1 million toward a targeted goal of $30 million.

NEW YORK (GenomeWeb) — Bio-Rad Laboratories has resolved a US Securities and Exchange Commission investigation into its violation of the Foreign Corrupt Practices Act due to the company's subsidiaries having made improper payments to foreign officials in Russia, Vietnam, and Thailand in order to

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

NEW YORK (GenomeWeb) – Agilent Technologies said in a regulatory document on Monday that an investigation by US regulators into possible infractions by the company's employees in China has ended without any enforcement actions by the agencies.

NEW YORK (GenomeWeb News) – Agilent Technologies has launched an investigation into activities of certain of its employees in China for possible infractions of US law, the company said in its Form 10-Q.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Bruker said this week it has found that certain employees in its Bruker Optics subsidiary bribed officials in China and the company has fired them.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.